Connor Clark & Lunn Investment Management Ltd. Makes New Investment in AnaptysBio, Inc. $ANAB

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 141,026 shares of the biotechnology company’s stock, valued at approximately $9,519,000.

A number of other hedge funds have also recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of AnaptysBio in the 2nd quarter worth about $124,473,000. Vanguard Group Inc. boosted its stake in AnaptysBio by 4.5% during the fourth quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock worth $74,855,000 after acquiring an additional 67,048 shares in the last quarter. State Street Corp boosted its stake in AnaptysBio by 20.6% during the fourth quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock worth $51,072,000 after acquiring an additional 180,042 shares in the last quarter. Affinity Asset Advisors LLC grew its holdings in AnaptysBio by 111.4% in the first quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock worth $52,132,000 after purchasing an additional 495,308 shares during the period. Finally, 683 Capital Management LLC grew its holdings in AnaptysBio by 18.5% in the fourth quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock worth $31,420,000 after purchasing an additional 101,093 shares during the period.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ANAB shares. UBS Group lifted their target price on shares of AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. TD Cowen reduced their price objective on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday. Piper Sandler lowered their price objective on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Leerink Partners set a $90.00 target price on AnaptysBio in a report on Friday, May 15th. Finally, Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Ten investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $80.00.

AnaptysBio Stock Performance

Shares of AnaptysBio stock opened at $58.00 on Thursday. The stock has a market capitalization of $1.72 billion, a PE ratio of -53.70 and a beta of 0.72. AnaptysBio, Inc. has a 52-week low of $11.40 and a 52-week high of $72.36. The company has a 50-day simple moving average of $58.58 and a two-hundred day simple moving average of $59.02.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.